skip to Main Content

October 1, 2020
Research in Action Awards 2020
Please join us at our annual, and first ever virtual, Research in Action Awards on Thursday, November 19, 2020. At this time of great turmoil and when activism to end infectious disease is more vital than ever, it’s so important to gather virtually to celebrate life, commemorate those we’ve lost,…

September 21, 2020
Advancing Access through Market Interventions: Lessons Learned from the GeneXpert Tuberculosis Test Buy-Down
Publication
This policy brief examines lessons learned from the Xpert MTB/RIF TB test buy-down and provides recommendations and pro-access conditions that should be applied to R&D funding, buy-down, and other market intervention agreements for COVID-19 diagnostics.

September 18, 2020
Public Investment in Bedaquiline Up to Five-Fold That of Johnson & Johnson
Statement / Press
Treatment Action Group’s independent, peer-reviewed analysis found public investment in the development of bedaquiline was up to five times that of Johnson and Johnson. This finding appears in the new PLOS ONE article, “Public Investments in the Clinical Development of Bedaquiline.”

September 16, 2020
Response to HUD’s Proposed Rule Change: Making Admission or Placement Determinations Based on Sex in Facilities Under Community Planning and Development Housing Programs
Letter / Comment
TAG joined numerous other public health and housing organizations in strongly opposing the proposed rule that would allow certain HUD-funded shelters to deny services to transgender people. HUD should withdraw this rule and work to ensure all people have access to shelter and housing, especially during a deadly pandemic.

September 13, 2020
Treatment Action Group Condemns Reported Bullying, Harassment, and Racism at Stop TB Partnership
Statement / Press
Treatment Action Group (TAG) strongly condemns alleged bullying, harassment, and racism directed toward staff and contractors of the Stop TB Partnership, as reported by The New York Times. As a long-term and current grantee of the Stop TB Partnership, we stand in solidarity with current and former staff and contractors…

September 4, 2020
TB Research Investments Provide Returns in Combating Both TB and COVID-19
Publication
As the COVID-19 pandemic continues to radically shift the global health landscape and alter government/donor commitments, TAG has released this timely brief to explore the impact of COVID-19 on TB research and development (R&D), and how tools, concepts, capacity, and infrastructure established through years of public and donor investments in…

September 2, 2020
Demanding a Higher Standard of TB Care
Webinar / Presentation
In these two webinars, Treatment Action Group (TAG) launched the two latest additions to our series of materials designed for community leaders, An Activist’s Guide to Treatment for Drug-Resistant Tuberculosis and An Activist’s Guide to Tuberculosis Diagnostic Tools.

August 6, 2020
Treatment Action Group Regrets NYC Health Commissioner Oxiris Barbot’s Resignation
Statement / Press
Treatment Action Group, the New York City-based research, policy, and advocacy organization, deplores the August 4, 2020 departure of New York’s Department of Health Commissioner, Dr. Oxiris Barbot, MD.

August 3, 2020
Letter to Sanofi CEO Calling for Patent Withdrawals on Critical TB Drugs
Letter / Comment
TAG and our French partners OTMeds (Observatoire de la transparence dans les politiques du médicaments) sent a letter to Sanofi CEO Paul Hudson calling on the company to reverse its efforts to patent two obvious combinations of two critical drugs to prevent tuberculosis: rifapentine and isoniazid.

July 28, 2020
An Activist’s Guide to Treatment for Drug-Resistant Tuberculosis
Publication
The 2020 updates to the World Health Organization (WHO) guidelines shifted the global standard of care for drug-resistant TB in a number of important ways. Our publication, An Activist’s Guide to Treatment for Drug-Resistant Tuberculosis, details these shifts and other important information about the new global standard of care for…

Back To Top